Ricevi le ultime notizie sulle azioni Redhill Biopharma con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di RDHL

Ultime notizie per

Redhill Biopharma

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma Ltd

Press Releases

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

Earnings

Small Cap

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

RDHL

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Akanda

Biofrontera

Clearmind Medicine

CNS Pharma

China Pharma Holding

Enveric Biosciences

Impact BioMedical

InMed Pharmaceuticals Inc. - Common Shares

InMed Pharmaceuticals

Jaguar Health

Lexaria Bioscience

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Nutriband

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

PainReform

SciSparc

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

VYNE Therapeutics

XORTX Therapeutics

Screenshot 2025-02-25 at 7.29.32 PM

Biotech

General

RedHill Licenses RHB-102 Worldwide Excluding North America To Hyloris For Up To $60M In Potential Milestone Payments Plus Royalties

Screenshot 2025-02-04 at 6.43.58 PM

BAYRY

New Prostate Cancer Hope? Bayer-Funded Phase 2 Study To Test Combination Of RedHill&#39;s Opaganib And Bayer&#39;s Darolutamide, To Overcome Androgen Resistance

Screenshot 2024-12-05 at 6.50.09 PM

News

Supreme Court Of New York Awards RedHill Biopharma Approx. $8 Million Plus Costs In Breach Of Contract Lawsuit

Screenshot 2024-10-14 at 5.39.36 PM

RedHill Biopharma Secures U.S. Government Funding Through BARDA To Advance Opaganib For Ebola Treatment

Screenshot 2024-08-22 at 5.32.58 PM

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Comments

Redhill Biopharma Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO